Psychopharmaka

  • Martin J. Lohse
  • Bruno Müller-Oerlinghausen
Chapter

Zusammenfassung

Die Psychopharmaka lassen sich in fünf große Gruppen unterteilen (Abbildung 39.1): Tranquillantien (ganz überwiegend Benzodiazepine), Antidepressiva, Neuroleptika und Psychostimulanzien sowie pflanzliche Psychopharmaka (überwiegend Johanniskrautextrakte). Hinzu kommen verschiedene kleinere Gruppen, so die vorzugsweise zur Langzeittherapie bzw. Prophylaxe affektiver Störungen eingesetzten sog. „Stimmungsstabilisierer“ wie z.B. Lithiumsalze und bestimmte Antiepileptika (z. B. Carbamazepin, Lamotrigin).
Open image in new window
Abbildung 39.1

Verordnungen von Psychopharmaka 2008. Gesamtverordnungen nach definierten Tagesdosen

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004): Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601.CrossRefGoogle Scholar
  2. Anonym (2003): Lithium-Therapie bei der manisch-depressiven Erkrankung: Immer noch der Standard? Arzneimittelbrief 37: 49–51.Google Scholar
  3. Anonym (2004): Escitalopram. Un isomère du citalopram, sans aucun avantage thérapeutique. Rev Prescrire 24: 325–328.Google Scholar
  4. Anonym (2005a): Antidepressiva: lebensgefährliche Placebos? Arznei-telegramm 36: 45–47.Google Scholar
  5. Anonym (2005b): Aripiprazole. Prescrire International 14: 163.Google Scholar
  6. Anonym (2006a): Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int 15: 168–172.Google Scholar
  7. Anonym (2008a): Kinder: Neuroleptikagebrauch steigt. Arzneitelegramm 39: 69–70.Google Scholar
  8. Anonym (2009): Psychopanacea? Prescrire Internat 18: 53.Google Scholar
  9. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005): Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3: 449–456.CrossRefPubMedGoogle Scholar
  10. Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2003): Empfehlungen zur Therapie von Angst-und Zwangsstörungen. 2. Aufl. Sonderheft Arzneiverordnung in der Praxis.Google Scholar
  11. Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2006a): Empfehlungen zur Therapie der Depression. 2. Aufl. Sonderheft Arzneiverordnung in der Praxis, im Druck.Google Scholar
  12. Arzneimittelkommission der deutschen Ärzteschaft (2006b): Hypersexualität unter Aripiprazol. Deutsches Ärzteblatt 103: A3518.Google Scholar
  13. Arzneimittelkommission der deutschen Ärzteschaft (2008): Stellenwert von Antidepressiva in der Depressionsbehandlung. Arzneiverordnung in der Praxis 35: 42–43.Google Scholar
  14. Baghai TC, Volz HP, Möller HJ (2006): Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7: 198–222.CrossRefPubMedGoogle Scholar
  15. Ban TA (2008): Comment on: ‚antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence‘. Int J Neuropsychopharmacol 11: 583–585; author reply 587–889.CrossRefPubMedGoogle Scholar
  16. Barbui C, Hotopf M (2001): Amitriptyline vs. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Brit J Psychiatry 178: 129–144.CrossRefGoogle Scholar
  17. Bauer M, Grof P, Müller-Oerlinghausen B (eds.) (2006) Lithium in Neuropsychiatry: The Comprehensive Guide. Taylor & Francis Books Ltd, Abingdon, (in print)Google Scholar
  18. Bauer M, Whybrow PC, Angst C, Verslani M, Möller H-J (2002): World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3: 5–43.CrossRefPubMedGoogle Scholar
  19. Baumann P (1996): Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31: 444–469.CrossRefPubMedGoogle Scholar
  20. Benkert O, Szegedi A, Kohnen R (2000): Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61: 656–663.PubMedGoogle Scholar
  21. Elliger TJ, Trott GE, Nissen G (1990): Prevalence of psychotropic medication in childhood and adolescence in the Federal Republic of Germany. Pharmacopsychiatry 23: 38–44.CrossRefPubMedGoogle Scholar
  22. EMEA (2005): Scientific Discussion vom 27.1.2005. Im Internet unter: www.emea.eu.int/humandocs/Humans/EPAR/cymbalta/cymbalta.htmGoogle Scholar
  23. Ernst CL, Goldberg JF (2004): Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 12: 14–41.PubMedGoogle Scholar
  24. Food and Drug Administration (FDA) (2007): FDA proposes new warnings about suicidal thinking, behaviour in young adults to take antidepressant medications. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html.Google Scholar
  25. Food and Drug Administration (FDA) (2008): Drug Safety Newsletter 1: 22–24.Google Scholar
  26. Frank E, Kupfer DJ, Perel JM (1990): Three-years outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47: 1093–1099.PubMedGoogle Scholar
  27. Fritze J (2009): Psychopharmaka-Verordnunge: Ergebnisse und Kommentare zum Arzneiverordnungsreport 2008. Psyhopharmakotherapie 16: 121–133.Google Scholar
  28. Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM (2000): The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61: 9–15.PubMedGoogle Scholar
  29. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Jockers-Scherübl MC, Kühn KU, Lemke M, Bechdolf A, Bender S, Degner D, Schlösser R, Schmidt LG, Schmitt A, Jäger M, Buchkremer G, Falkai P, Klingberg S, Köpcke W, Maier W, Häfner H, Ohmann C, Salize HJ, Schneider F, Möller HJ; German Study Group on First-Episode Schizophrenia (2007): Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 68: 1763–1774.CrossRefPubMedGoogle Scholar
  30. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE, Lohr KN (2008): Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 31: 851–865.CrossRefPubMedGoogle Scholar
  31. Geddes J (2009) BALANCE: Initial results and methodological aspects of trials of maintenance treatments. Bipolar Disorders 11(Suppl. 1): 6.Google Scholar
  32. Geddes J, Freemantle N, Harrison P et al (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321: 1371–1376.CrossRefPubMedGoogle Scholar
  33. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library-Issue 1.Google Scholar
  34. Gentile S (2007): Atypical antipsychotics for the treatment of bipolar disorders. CNS Drugs 21: 367–387.CrossRefPubMedGoogle Scholar
  35. Gibbons RD, Brown CH, Hur K, Marcus SM, Baumikh DK, Erkenmann JJ (2007): Early evidence on the effects of regulators’ suicidality warnings on prescriptions and suicide in children and adolescents. Am J Psychiatry 164: 1356–1363.CrossRefPubMedGoogle Scholar
  36. Gonzalez-Pinto A, Mosquera F, Alonso M, Lopez P, Ramírez F, Vieta E, Baldessarini RJ (2006): Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 8: 618–624CrossRefPubMedGoogle Scholar
  37. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467–1473.CrossRefPubMedGoogle Scholar
  38. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA (2006): The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163: 813–821.CrossRefPubMedGoogle Scholar
  39. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group (2008): Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085–1097.CrossRefPubMedGoogle Scholar
  40. Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796.PubMedGoogle Scholar
  41. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003): Longacting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125–1132.CrossRefPubMedGoogle Scholar
  42. Kassenärztliche Bundesvereinigung (2006): Wirkstoff aktuell: Quetiapin (Seroquel®). Ausgabe 05/2006.Google Scholar
  43. Kassenärztliche Bundesvereinigung (2007): Bekanntmachungen: Rahmenvorgaben nach § 84 Absatz 7 SGB V und Vereinbarung nach § 84 Abs. 7a SGB V — Arzneimittel — für das Jahr 2007 vom 19. September 2006. Dtsch Ärztebl 104: A 69–A 72.Google Scholar
  44. Kassenärztliche Bundesvereinigung (2008): Wirkstoff aktuell: Venlafaxin (Trevilor®). Ausgabe 03/2008.Google Scholar
  45. Kessler RC, Demier O, Frank RG, Olfson M, Pincus HA, Walters EE et al (2005): Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 352:2515–2523.CrossRefPubMedGoogle Scholar
  46. Kimko HC, Cross JT, Abernethy DR (1999): Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmakokinet 37: 457–470.CrossRefGoogle Scholar
  47. Kirsch I, Deacon BJ, Huedo-Medina TB et al. (2008): Initial severity and antidepressant benefit: a meta-analysis of data submitted to the Food and Drug Administration. PloS Med 5: e45.CrossRefPubMedGoogle Scholar
  48. Knopf H, Melchert H-U (2003): Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Robert-Koch-Institut Berlin (Hrsg).Google Scholar
  49. Lapierre YD (1989): A review of trimipramine 30 years of clinical use. Drugs 38(suppl 1): 17–24.CrossRefPubMedGoogle Scholar
  50. Laux G, Müller WE, Eckermann G et al (2009): Paliperidon EL — eine klinisch-pharmakologische Differenzierung gegenüber Risperidon. Psychopharmakotherapie 16: 70–78.Google Scholar
  51. Leon AC, Shear MK, Portera L, Klerman GL (1993): Effect size as a measure of symptom-specific drug change in clinical trials. Psychopharmacol Bull 29: 163–167.PubMedGoogle Scholar
  52. Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B et al (2001): The European acamprosate trials. Conclusions for research and therapy. J Biomed Sci 8: 89–95.CrossRefPubMedGoogle Scholar
  53. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009): Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41.CrossRefPubMedGoogle Scholar
  54. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and metaanalysis. Lancet 361: 1581–1589.CrossRefPubMedGoogle Scholar
  55. Leucht S, Komossa K (2006): Methodik und kritische Interpretation psychopharmakologischer Schizophreniestudien. Psychopharmakotherapie 13: 231–240.Google Scholar
  56. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1233.CrossRefPubMedGoogle Scholar
  57. Linde K, Berner M, Egger M, Mulrow C (2005): St John’s wort for depression: metaanalysis of randomised controlled trials. Br J Psychiatry 186: 99–107.CrossRefPubMedGoogle Scholar
  58. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F et al (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and metaanalysis. Brit Med J 326: 1014–1019.CrossRefPubMedGoogle Scholar
  59. Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software.Google Scholar
  60. Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835.PubMedGoogle Scholar
  61. McCue RE, Waheed R, Urcuyo L et al. (2006): Comparative effectiveness of secondgeneration antipsychotics and haloperidol in acute schizophrenia. Brit J Psychiatry 189: 433–440.CrossRefGoogle Scholar
  62. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators (2006): Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610.CrossRefPubMedGoogle Scholar
  63. Medawar C, Hardon A, Herxheimer A (2004): Depressing research. Lancet 363: 2087.CrossRefPubMedGoogle Scholar
  64. Molina BSG, Florey K, Hinshaw SP, Greiner, AR, Arnold E, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliot GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007): Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46: 1028–1040.CrossRefPubMedGoogle Scholar
  65. Möller HJ, Baldwin DS, Goodwin G, Kasper S, Okasha A, Stein DJ, Tandon R, Versiani M; WPA Section on Pharmacopsychiatry (2008): Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci 258Suppl 3: 3–23.CrossRefPubMedGoogle Scholar
  66. Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolamtreated group. J Clin Psychopharmacol 21: 59–65.CrossRefPubMedGoogle Scholar
  67. Moncrieff J (2001): Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 189: 288–295.CrossRefPubMedGoogle Scholar
  68. Moncrieff J (2008): Steht die Psychiatrie zum Verkauf an? Sozialpsychiatr Informationen 38: 8–18.Google Scholar
  69. Moncrieff J, Kirsch I (2005): Efficacy of antidepressants in adults. BMJ 331: 155–157.CrossRefPubMedGoogle Scholar
  70. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfron M (2007): National trends in the outpatient diagnosis and treatment of bipolar disorders in youths. Arch Gen Psychiatry 64: 1032–1039.CrossRefPubMedGoogle Scholar
  71. Royal College of Psychiatrists, British Psychological Society (2006): Schizophrenia. Full national clinical guideline on core interventions in primary and secondary care. Internet: http://guidance.nice.org.uk/CG1/guidance/pdf/EnglishGoogle Scholar
  72. Safer DJ (2000): Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry 12: 55–62.PubMedGoogle Scholar
  73. Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W, Goodwin G, Grunze H, Knapp M, Leonard BE, Lieberman J, Nakane Y, Pinder RM, Schatzberg AF, Svestka J, Baumann P, Ghalib K, Markowitz JC, Padberg F, Fink M, Furukawa T, Fountoulakis KN, Jensen P, Kanba S, Riecher-Rössler A (2007): Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol. 2007 Dec; 10Suppl 1:S1–S–207.PubMedGoogle Scholar
  74. Sass H, Soyka M, Mann K, Zieglgansberger W (1996): Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53: 673–680.PubMedGoogle Scholar
  75. Schiander M (2007): Aktuelle Daten zur medizinischen Versorgung von Kindern und Jugendlichen mit ADHS in Deutschland — Administrative Prävalenz, beteiligte Arztgruppen und Arzneimitteltherapie. Psychoneuro 33: 412–415.CrossRefGoogle Scholar
  76. Schöpf J, Müller-Oerlinghausen B (2005): Standardpräparate der Psychopharmakotherapie. Lithium. 2. Aufl. Springer-Verlag, Berlin Heidelberg New YorkGoogle Scholar
  77. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396–404.CrossRefPubMedGoogle Scholar
  78. Søndergård I; Lopez AG, Kessing LU (2008): Mood-stabilizing pharmacological treatment in bipolar disorder and risk of suicide. Bipol Dis 10: 87–94.Google Scholar
  79. Spielmans GI (2008): Duloxetine does not relieve painful psychological symptoms in depression. A metaanalysis. Psychother Psychosom 77: 12–16.CrossRefPubMedGoogle Scholar
  80. Stip E (2000): Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J Psychiatry Neurosci 25: 137–153.PubMedGoogle Scholar
  81. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators (2006): Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611–622.CrossRefPubMedGoogle Scholar
  82. Svensson S, Mansfield PR (2004): Escitalopram: superior to citalopram or a chiral chimera? Psychother Psychosom 73: 10–16.CrossRefPubMedGoogle Scholar
  83. Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, McCracken J, McGough J, Riddle M, Ghuman J, Cunningham C, Wigal S (2006): Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 45: 1304–1313.CrossRefPubMedGoogle Scholar
  84. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA (2008): What CATIE Found: Results From the Schizophrenia Trial. Psychiatr Serv 59: 500–506.CrossRefPubMedGoogle Scholar
  85. Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26.CrossRefPubMedGoogle Scholar
  86. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ; Section of Pharmacopsychiatry, World Psychiatric Association (2008): World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 100: 20–38.CrossRefPubMedGoogle Scholar
  87. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000): Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35: 202–209.PubMedGoogle Scholar
  88. Thase ME (2003): Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 64(Suppl 2): 3–7.Google Scholar
  89. Thase ME, Entsuah R, Rudolph RL (2001): Remission rates during treatment with venlafaxine or selective reuptake inhibitors. Br J Psychiatry 178: 234–241.CrossRefPubMedGoogle Scholar
  90. Turner EH, Matthews AM, Linardatos E et al. (2008): Selective publication of antidepressant triuals and its influence on apparent efficacy. N Engl J Med 358: 252–260.CrossRefPubMedGoogle Scholar
  91. Volovka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP et al. (2004): Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65: 57–61.CrossRefGoogle Scholar
  92. Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuropsychopharmacol 10: 211–217.CrossRefPubMedGoogle Scholar
  93. Walsh BT, Seidman SN, Sysko R, Gould M (2002): Placebo response in studies of major depression. Variable, substantial and growing. JAMA 287: 1840–1847.CrossRefPubMedGoogle Scholar
  94. Weinmann S (2008): Erfolgsmythos Psychopharmaka. Warum wie Medikamente in der Psychiatrie neu bewerten müssen. Psychiatrie Verlag, Bonn.Google Scholar
  95. Wetterling T (2001): Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24: 59–73.CrossRefPubMedGoogle Scholar
  96. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Colgrove A, Boddington E (2004): Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363: 1341–1345.CrossRefPubMedGoogle Scholar
  97. Williams JW Jr, Mulrow CD, Chiquette E, Hitchcock Noël P, Aguilar C, Cornell J (2000): Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 132: 743–756.PubMedGoogle Scholar
  98. Wolter D (2009): Risiken von Antipsychotika im Alter speziell bei Denzen. Eine Übersicht. Zschr. Gerontopsychologie u-psychiatrie 22: 17–56.CrossRefGoogle Scholar
  99. Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004): Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol 18: 262–276.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2009

Authors and Affiliations

  • Martin J. Lohse
    • 1
  • Bruno Müller-Oerlinghausen
    • 2
  1. 1.Institut für Pharmakologie und Toxikologie der Universität WürzburgWürzburg
  2. 2.Berlin

Personalised recommendations